$637M to Power DeepIntent’s Next Chapter
Vitruvian’s majority stake seeks to fuels AI-driven healthcare advertising and patient-centered media innovation.
Healthcare adtech platform DeepIntent has announced a $637 million investment from private equity firm Vitruvian Partners, marking one of the largest funding rounds in the healthcare media space to date. Vitruvian will acquire a majority stake in the company, with DeepIntent continuing to operate independently under founder and CEO Chris Paquette.
When speaking with solli CEO Rich Springham, DeepIntent’s Chris Paquette emphasized that the partnership with Vitruvian is about more than capital—it’s about accelerating innovation in healthcare advertising. As he put it:
“At DeepIntent, our mission has always been rooted in improving patient outcomes by connecting life sciences companies, providers, and patients in smarter, more meaningful ways. With Vitruvian’s support, we’re accelerating the integration of generative AI and real-world data into our platform to give healthcare marketers the tools so they can deliver information with greater accuracy, relevance, and timeliness. This isn’t just about more efficient advertising; it’s about ensuring patients and providers have the knowledge they need to make better health decisions.”
Founded in 2016, DeepIntent has become a central player in connecting pharmaceutical and healthcare brands to patients and HCPs through data-driven advertising. The company’s platform integrates real clinical data, media decisioning, and AI-powered tools—supporting campaigns for 19 of the top 20 global life sciences companies.
Why It Matters for Pharma Media
The deal signals both confidence and competition in healthcare adtech. For pharma marketers, it reinforces several important shifts:
- AI Investment at Scale: DeepIntent intends to build and integrate new generative AI tools within its platform. This points to a future where campaign planning, creative optimization, and compliance checks may be increasingly automated.
- Audience Precision: By combining clinical data with media execution, DeepIntent is positioned to expand capabilities for targeting both patient and HCP audiences with greater accuracy.
- Market Confidence: At a time when economic uncertainty has cooled many adtech investments, a $637M funding round suggests strong belief in the growth of patient-centered, data-driven pharma media.
The Bigger Picture
The investment arrives just weeks after DeepIntent launched a free ad-supported TV product aimed at healthcare advertisers, expanding pharma’s ability to reach audiences on premium streaming services. Coupled with new AI development, this could accelerate innovation in omnichannel strategies where Connected TV, streaming, and clinical data intersect.
solli’s Final Thoughts
For pharma media leaders, the takeaway is clear: the future of healthcare advertising is being built at the intersection of AI, compliance, and clinical data. Monitoring how platforms like DeepIntent evolve will be critical for navigating new opportunities—while managing the risks of privacy, competition, and transparency.
Read the full press release here.
